ライフサイエンスコーパス: prostaglandin E2

1 the biosynthesis of prostacyclin (PGI2) and prostaglandin E2.

2 ssed cyclooxygenase 1/2 and basally secreted prostaglandin E2.

3 key modulator of inflammation and immunity, prostaglandin E2.

4 oduction/release of TNF-alpha, IL-1beta, and prostaglandin E2.

5 inflammatory factors, including TGF-beta and prostaglandin E2.

6 mpaired levels of cysteinyl-leukotrienes and prostaglandin E2.

7 h cyclooxygenase (COX)-2 in the synthesis of prostaglandin E2.

8 ajor histocompatibility complex class II and prostaglandin E2.

9 ction of proinflammatory effectors including prostaglandin E2.

10 rly induces the beta-catenin pathway through prostaglandin E2.

11 nd the cyclooxygenase-associated metabolites prostaglandin E2, 11-hydroxyeicosatetraenoic acid, and t

12 (HCC) growth by 15-PGDH through the 15-keto-prostaglandin E2 (15-keto-PGE2)/peroxisome proliferator-

13 Although suppression of prostaglandin E2 accounts for the protective effect of m

14 a result of autonomic responses triggered by prostaglandin E2 action on EP3 receptors expressed by ne

15 Also, PGE(2) (prostaglandin E2) added to differentiating MM6 cells up-

16 PPARgamma) activator rosiglitazone (Rosi) or prostaglandin E2 analog (16,16-dimethyl PGE2) to adipose

17 Aqueous and vitreous levels of prostaglandin E2 and 16 other inflammatory cytokines imp

18 Prostaglandin E2 and bradykinin can activate airway sens

19 n were performed and included measurement of prostaglandin E2 and cytosolic phospholipase A2 activity

20 isruption of the protein's ability to induce prostaglandin E2 and cytosolic phospholipase A2 synthesi

21 sident peritoneal macrophages, prostacyclin, prostaglandin E2 and leukotriene C4 were produced within

22 portantly, we discovered that Galphaq-linked prostaglandin E2 and leukotriene D4 receptors also regul

23 demonstrated increased urinary excretion of prostaglandin E2 and metabolites.

24 tantly, MKO(GFAP) mice exhibit reduced brain prostaglandin E2 and pro-inflammatory cytokine levels up

25 tion initiating mediators leukotriene B4 and prostaglandin E2 and pro-resolving mediators resolvin D1

26 1 sensitization to the inflammatory mediator prostaglandin E2 and the chemotherapeutic drug oxaliplat

27 Prostaglandin E2 and thromboxane A2, as well as total AP

28 nalogues, and the cyclooxygenase metabolites prostaglandin E2 and thromboxane B2 differed at baseline

29 Because prostaglandin E2 and tumor necrosis factor-alpha are als

30 COX2 is critical for the secretion of prostaglandin E2 and was strongly induced by H(2)O(2) or

31 genesis and involves FGF receptor-3 (FGFR3), prostaglandin-E2 and interaction between estrogen recept

32 ammatory lipid mediators, Leukotriene B4 and Prostaglandin E2, and a concomitant decrease of resolvin

33 n explants were stimulated with IL-1beta and prostaglandin E2, and their effects on the release of CO

34 lammatory lipid mediators leukotriene B4 and prostaglandin E2 are elevated in the chronic spinal cord

35 We show that COX-2 and prostaglandin E2 are required for C1P-mediated increases

36 evelopmentally regulated by the inflammatory prostaglandin E2, but in different ways.

37 accelerate thrombogenesis, while suppressing prostaglandin E2, but increasing biosynthesis of PGI2.

38 Dilation is mediated by prostaglandin E2, but requires nitric oxide release to s

39 ia-synapse cross talk requires production of prostaglandin E2 by microglia, leading to the activation

40 dsRNA-induced WIHN and Wnt7b, and exogenous prostaglandin E2 can rescue WIHN and Wnt7b.

41 inhibited mechanical hyperalgesia induced by prostaglandin E2, carrageenan-induced hyperalgesia, and

42 ponses to capsaicin but reduced responses to prostaglandin E2 compared with healthy volunteers.

43 e with the loss of the antifibrotic mediator prostaglandin E2 contributes to the fibrotic process in

44 Both AREG and prostaglandin E2 converge to activate signaling through

45 The inflammatory cyclooxygenase/prostaglandin E2 (COX/PGE2) pathway has been implicated

46 otriene B4 , 11-dehydro-thromboxane B2 , and prostaglandins E2 , D2 , and F2alpha and their metabolit

47 ide lipase (ATGL) activity in neutrophils in prostaglandin E2-dependent and -independent manners.

48 16,16-Dimethyl prostaglandin E2 (dmPGE2) was previously identified to b

49 of hematopoietic grafts with 16-16 dimethyl prostaglandin E2 (dmPGE2).

50 pressed biosynthesis of prostaglandin I2 and prostaglandin E2, elevated blood pressure, and accelerat

51 izes prostanoid prostaglandin D2 (DP)1, DP2, prostaglandin E2 (EP)1, EP4, prostaglandin F2alpha, and

52 Prostaglandin E2 , EP2 agonists and EP4 agonists inhibit

53 with cardiomyocyte-selective knockout of the prostaglandin E2 EP4 receptor sub-type (EP4 KO) exhibit

54 induced by diverse pronociceptive mediators, prostaglandin E2, epinephrine, TNFalpha, and interleukin

55 eased medullary COX-2 expression and urinary prostaglandin E2 excretion and developed salt-sensitive

56 , increased free water reabsorption, urinary prostaglandin E2 excretion, and reduced excretion of ser

57 sociated with PGD, four of which were in the prostaglandin E2 family of genes.

58 UV-induced prostaglandin E2 has been implicated as an intermediary

59 The role of prostaglandin E2 in immune regulation has been better de

60 egulated increase in expression of Cox-2 and prostaglandin E2 in MDSCs in mediating this effect.

61 Prostaglandin E2 increased in controls and EPI group and

62 As a positive control, serosal 1 muM prostaglandin E2 increased mucin release to ~400% of the

63 Elevation of baseline urinary metabolite of prostaglandin E2, indicating activation of the COX-2 pat

64 monstrate that paracrine signaling involving prostaglandin E2-induced cAMP generation has the potenti

65 terminal to mediate a marked prolongation of prostaglandin E2-induced hyperalgesia.

66 obesity-associated and tumor-derived factor prostaglandin E2, inhibits p53 in the breast adipose str

67 on of cultured small-diameter DRG neurons by prostaglandin E2 is also prevented and reversed by HMWH.

68 In other tissues, prostaglandin E2 is an important effector of regeneratio

69 Prostaglandin E2 is now widely recognized to play critic

70 Prostaglandin E2 level was significantly increased in CS

71 Functionally, aortic Leukotriene B4 and Prostaglandin E2 levels correlated with traits of plaque

72 with clinically approved drugs that augment prostaglandin E2 levels in these settings prevented acut

73 Plaa-null mice were generated and prostaglandin E2 levels were measured in different tissu

74 Urinary metabolite of prostaglandin E2 may be able to identify patients who co

75 phorylation of PREX1 after isoproterenol and prostaglandin E2-mediated GPCR activation is partially P

76 d potently mitigate experimental colitis via prostaglandin E2-mediated immunosuppression.

77 oncentrations counterregulated adenosine and prostaglandin E2-mediated inhibition of ERK1/2 activatio

78 omponents, the enantioselective synthesis of prostaglandin E2 methyl ester has been achieved through

79 Inflammatory mediators such as prostaglandin-E2 or bradykinin cause hyperalgesia by act

80 etoricoxib on urinary excretion of tetranor-prostaglandin E2 (P < .001).

81 h and bone density (P <0.01), enhanced 7-day prostaglandin E2 (P <0.01), and reduced 28-day inflammat

82 regnancy, including the initiation of labor, prostaglandin E2 (PGE(2)) and prostaglandin F2alpha (PGF

83 The inflammatory prostaglandin E2 (PGE(2)) EP2 receptor is a master suppr

84 algesia induced by the inflammatory mediator prostaglandin E2 (PGE(2)) in male and female rats.

85 Prostaglandin E2 (PGE(2)) is produced in the airway duri

86 We found that the prostaglandin E2 (PGE(2)) receptors EP2 and EP4 were upr

87 h increased levels of interleukin (IL)-6 and prostaglandin E2 (PGE(2)), 2 inflammatory mediators know

88 Nitric oxide (NO) and prostaglandin E2 (PGE(2)), downstream products, were als

89 We determined vitreous levels of prostaglandin E2 (PGE(2)), VEGF, and 15 other cytokines

90 glandins, including the pro-algesic mediator prostaglandin E2 (PGE(2)), was decreased in myeloid cell

91 flammatory mediators including cytokines and prostaglandin E2 (PGE(2)), with limited side effects ass

92 Prostaglandin E2 (PGE2 ) has been shown to inhibit IgE-d

93 enase-2 (COX-2) and its prostanoid products, prostaglandin E2 (PGE2 ) in particular, are key contribu

94 89 +/- 17.47 pg/mg protein; P <0.05); and 3) prostaglandin E2 (PGE2) (LPS: 159.20 +/- 38.70 pg/mg wet

95 We found that prostaglandin E2 (PGE2) accumulates in the CM in a time-

96 Mechanistically, tumor-derived prostaglandin E2 (PGE2) acted selectively on EP2 and EP4

97 The two synthetic pathways are connected by prostaglandin E2 (PGE2) activation of the aromatase enzy

98 We detected high urinary prostaglandin E2 (PGE2) and ATP levels in Atp6v1b1-/- mi

99 The EP3 receptor is stimulated by prostaglandin E2 (PGE2) and couples to G-proteins of the

100 ing the degradation of inflammation mediator prostaglandin E2 (PGE2) and other prostanoids.

101 nhanced biosynthesis of eicosanoids, such as prostaglandin E2 (PGE2) and PGF2alpha, precedes the onse

102 also measured levels of the PUFA metabolites prostaglandin E2 (PGE2) and resolvins.

103 Peritoneal fluid concentrations of prostaglandin E2 (PGE2) are higher in women with endomet

104 We describe an unexpected role for prostaglandin E2 (PGE2) as a negative regulator of retin

105 Here we describe prostaglandin E2 (PGE2) as a regulator of endodermal fat

106 Prostaglandin E2 (PGE2) augments distinct inspiratory mo

107 Here we demonstrate in vivo that prostaglandin E2 (PGE2) can differentially increase the

108 Inflammation-induced release of prostaglandin E2 (PGE2) changes breathing patterns and t

109 Proinflammatory lipid mediators including prostaglandin E2 (PGE2) contribute to the establishment

110 actor A (VEGF-A), interleukin 10 (IL-10) and prostaglandin E2 (PGE2) cooperatively induced FasL expre

111 Prostaglandin E2 (PGE2) disrupts TGFbeta signaling and s

112 the cyclooxygenase (COX)-derived eicosanoid prostaglandin E2 (PGE2) drives cirrhosis-associated immu

113 cell activation via producing high level of prostaglandin E2 (PGE2) due to their thousands-fold high

114 The endogenous lipid mediator prostaglandin E2 (PGE2) exerts anti-fibrotic effects, in

115 ase (mPGES)-1 is responsible for the massive prostaglandin E2 (PGE2) formation during inflammation.

116 cible enzyme that catalyzes the formation of prostaglandin E2 (PGE2) from prostaglandin H2 (PGH2).

117 Prostaglandin E2 (PGE2) has been reported to play an ess

118 Prostaglandin E2 (PGE2) has been shown to enhance IL-17

119 Prostaglandin E2 (PGE2) has emerged as a principal media

120 ical hyperalgesia and marked prolongation of prostaglandin E2 (PGE2) hyperalgesia, a key feature of h

121 nduction of cyclooxygenase (COX)-2-dependent prostaglandin E2 (PGE2) in human DCs.

122 vestigated the contribution of COX-2-derived prostaglandin E2 (PGE2) in the formation of a premetasta

123 Here we identified prostaglandin E2 (PGE2) in the tumor as a key mediator o

124 induced a large increase in the excretion of prostaglandin E2 (PGE2) in urine, which was suppressed i

125 ntestine with 5-hydroxytryptamine (5-HT) and prostaglandin E2 (PGE2) induced goblet cell exocytosis f

126 sing activities, we found that tumor-derived prostaglandin E2 (PGE2) induces nuclear accumulation of

127 we report that the proinflammatory cytokine prostaglandin E2 (PGE2) induces the malignant SN12C, but

128 Prostaglandin E2 (PGE2) is a key mediator in inflammator

129 ted insulin secretion (GSIS), its metabolite prostaglandin E2 (PGE2) is a known inhibitor.

130 Prostaglandin E2 (PGE2) is a lipid mediator of inflammat

131 Prostaglandin E2 (PGE2) is a pleiotropic lipid mediator

132 Prostaglandin E2 (PGE2) is a potent lipid mediator that

133 Prostaglandin E2 (PGE2) is an important biological media

134 Here we show that Prostaglandin E2 (PGE2) is an inflammatory cytokine that

135 n strongly linked to adhesion formation, and Prostaglandin E2 (PGE2) is associated with both adhesion

136 Prostaglandin E2 (PGE2) is associated with proliferation

137 Prostaglandin E2 (PGE2) is derived from arachidonic acid

138 ly induced priming is detected not only when prostaglandin E2 (PGE2) is presented to the peripheral n

139 Prostaglandin E2 (PGE2) is regarded as the main mediator

140 Proinflammatory prostaglandin E2 (PGE2) is secreted by many cell types a

141 strated that the immunomodulatory eicosanoid prostaglandin E2 (PGE2) is synergistically increased dur

142 effect of MSK1/2 knockout was seen on plasma prostaglandin E2 (PGE2) levels following intraperitoneal

143 cholamines induce inflammation by increasing prostaglandin E2 (PGE2) levels in ovarian cancer cells.

144 X-1 and PGIS protein expression and PGI2 and prostaglandin E2 (PGE2) levels in the kidney and renal v

145 Local and systemic interleukin-6 (IL-6) and prostaglandin E2 (PGE2) levels were significantly elevat

146 ted the effects of the inflammatory mediator prostaglandin E2 (PGE2) on colorectal CSC development an

147 ers described a positive regulatory role for prostaglandin E2 (PGE2) on HSC function ex vivo.

148 o-inflammatory effects of macrophage-derived prostaglandin E2 (PGE2) on Th17 cells.

149 Modulating levels of prostaglandin E2 (PGE2) or PGB2 restricted distal segmen

150 Accumulation of COX-2-derived prostaglandin E2 (PGE2) parallels the substantial increa

151 vate, via Tpl2, the cyclooxygenase-2 (Cox-2)-prostaglandin E2 (PGE2) pathway, which we show here to b

152 fibroblast via the cyclooxygenase 2 (COX-2)/prostaglandin E2 (PGE2) pathway.

153 vitalization of the cyclooxygenase (COX) and prostaglandin E2 (PGE2) pathway.

154 We tested the hypothesis that astrocytic prostaglandin E2 (PgE2) plays a key role for cerebrovasc

155 ntent, total antioxidant capacity, effect on prostaglandin E2 (PGE2) production and anticancer cell p

156 f iPSC-MSCs and BM-MSCs were associated with prostaglandin E2 (PGE2) production and cell-cell contact

157 endothelial cells, we demonstrate that local prostaglandin E2 (PGE2) production in deep brain areas,

158 on of cyclooxygenase 2 (COX-2) and resultant prostaglandin E2 (PGE2) production.

159 Activation of EP2 receptors by prostaglandin E2 (PGE2) promotes brain inflammation in n

160 Prostaglandin E2 (PGE2) promotes Th17 expansion while ot

161 expression, whereas increased production of prostaglandin E2 (PGE2) promotes the differentiation of

162 The EP4 subtype of prostaglandin E2 (PGE2) receptors (EP4-R) is a particula

163 ase-2 (COX-2) activity and activation of the prostaglandin E2 (PgE2) receptors EP2 and EP4.

164 py effectively induces apoptosis, associated prostaglandin E2 (PGE2) release paradoxically promotes n

165 ge (0.57-fold Nrf-2 and 0.34-fold HO-1), and prostaglandin E2 (PGE2) release was increased in samples

166 is responsible for arachidonic acid (AA) and prostaglandin E2 (PGE2) release.

167 ypersensitivity was impaired, and subsequent prostaglandin E2 (PGE2) response was blunted.

168 Here we found prostaglandin E2 (PGE2) secreted by osteoblastic cells a

169 ion of infected apoptotic cells (IACs) drive prostaglandin E2 (PGE2) secretion to generate Th17 cells

170 The pain mediator prostaglandin E2 (PGE2) sensitizes nociceptive pathways

171 e results from LPS-induced the production of prostaglandin E2 (PGE2) show that, esculetin, curcumin a

172 pithelial cell culture system, we found that prostaglandin E2 (PGE2) signaling through one of its rec

173 In human aortic smooth muscle cells, prostaglandin E2 (PGE2) stimulates adenylyl cyclase (AC)

174 Prostaglandin E2 (PGE2) stimulates HSC renewal and engra

175 Platelet-induced COX-2-dependent prostaglandin E2 (PGE2) synthesis in HT29 cells was invo

176 is in mouse neonates through upregulation of prostaglandin E2 (PGE2) synthesis pathway consisting of

177 dothelium followed by COX1-mediated cerebral prostaglandin E2 (PGE2) synthesis.

178 eurological conditions, mainly via producing prostaglandin E2 (PGE2) that activates four membrane rec

179 TLR4 ligand, induces macrophages to generate prostaglandin E2 (PGE2) through inducible COX-2 and micr

180 Fever occurs upon binding of prostaglandin E2 (PGE2) to EP3 receptors in the median p

181 COX-2 overexpression or Prostaglandin E2 (PGE2) treatment increased beta1-integr

182 We reported previously that prostaglandin E2 (PGE2) up-regulates IL-23 in vitro in b

183 significantly increased, while the level of prostaglandin E2 (PGE2) was decreased.

184 nsforming growth factor beta (TGF-beta), and prostaglandin E2 (PGE2) were higher in patients with DCL

185 phage inflammatory protein (MIP)-1alpha, and prostaglandin E2 (PGE2) were measured.

186 nthesis and receptor pathways for eicosanoid prostaglandin E2 (PGE2) were more highly induced in IL-1

187 hanges in the PR pathway on the secretion of prostaglandin E2 (PGE2), a key factor for promoting cell

188 Prostaglandin E2 (PGE2), a potent lipid signaling molecu

189 aim of this study was to analyze the role of prostaglandin E2 (PGE2), a prostaglandin known to be inc

190 lones, with a focus on modulatory effects of prostaglandin E2 (PGE2), and evaluate progeny for p53 mu

191 ls overexpress cyclooxygenase-2, overproduce prostaglandin E2 (PGE2), and exhibit defective intracell

192 Although immunoregulatory factors, such as Prostaglandin E2 (PGE2), and their mechanisms of action

193 looxygenases (COXs) and their final product, prostaglandin E2 (PGE2), are known to play important rol

194 macrophages, resulting in enhanced levels of prostaglandin E2 (PGE2), autocrine activation of the mac

195 s: estradiol-17-beta-glucuronide (E17betaG), prostaglandin E2 (PGE2), cholecystokinin 8 (CCK8), and v

196 vs. patient 0.1 ng/ml) and leukocytes [e.g., prostaglandin E2 (PGE2), control 21.9 +/- 7.4 ng/ml vs.

197 including chemokines, cytokines, COX-2, and prostaglandin E2 (PGE2), in vivo.

198 scued by the addition of arachidonic acid or prostaglandin E2 (PGE2), indicating a phospholipase-depe

199 a-intercalated cells, via release of ATP and prostaglandin E2 (PGE2), influence the activity of trans

200 valuate levels of four major labor triggers, prostaglandin E2 (PGE2), interleukin (IL)-1beta, IL-6, a

201 rs, such as vasoactive intestinal peptide or prostaglandin E2 (PGE2), regulate intestinal anion/fluid

202 Previously, we revealed that prostaglandin E2 (PGE2), released during hypercapnic cha

203 at the key products of NOS2 and COX2, NO and prostaglandin E2 (PGE2), respectively, promote feed-forw

204 ed autologous T cells in a manner relying up prostaglandin E2 (PGE2), STAT-3, and superoxide.

205 this enzyme, the proinflammatory eicosanoid prostaglandin E2 (PGE2), stimulates adipose tissue aroma

206 al cells with M27 increases the secretion of prostaglandin E2 (PGE2), the enzymatic product of Ptges,

207 nd were treated with vehicle, diclofenac, or prostaglandin E2 (PGE2), the most important COX-2 produc

208 We observed that prostaglandin E2 (PGE2), through its receptor EP4, is do

209 ce the synthesis of the small lipid mediator prostaglandin E2 (PGE2), which alters the host T cell re

210 ry enzyme responsible for the degradation of prostaglandin E2 (PGE2), which is known to promote tumor

211 Human amnion fibroblasts produce abundant prostaglandin E2 (PGE2), which plays a crucial role in p

212 Prostaglandin E2 (PGE2), which stimulates HSPC survival

213 similar to that of intraplantar injection of prostaglandin E2 (PGE2), which was significantly attenua

214 Among these is prostaglandin E2 (PGE2), which, in addition to its role

215 gene-7 (MIG-7) protein as critical for COX-2/prostaglandin E2 (PGE2)- and Akt/GSK-3beta-dependent tum

216 volves calcium efflux and stimulation of the prostaglandin E2 (PGE2)-cyclic adenosine monophosphate (

217 ted macrophages and expressed high levels of prostaglandin E2 (PGE2)-forming enzymes microsomal PGE2

218 saccharide-, parathyroid hormone (PTH)-, and prostaglandin E2 (PGE2)-induced expression of MMP-13 in

219 al of this study was to functionally compare prostaglandin E2 (PGE2)-sensitive receptors in human pri

220 levels of sphingosine-1-phosphate, CCL20 and prostaglandin E2 (PGE2).

221 ound-inflammation-induced trophic signals is prostaglandin E2 (PGE2).

222 involving reactive oxygen species (ROS) and prostaglandin E2 (PGE2).

223 ll production of the COX-2 synthetic product prostaglandin E2 (PGE2).

224 f cyclooxygenase-2 (COX-2) and production of prostaglandin E2 (PGE2).

225 result of elevated levels of COX-2-dependent prostaglandin E2 (PGE2).

226 IL-8 pathway by increasing the production of prostaglandin E2 (PGE2).

227 tion of living cell growth involves secreted prostaglandin E2 (PGE2).

228 tor, glycolipid alpha-GalCer, and endogenous prostaglandin E2 (PGE2).

229 ciated with production of the lipid mediator prostaglandin E2 (PGE2).

230 lective antagonist and imitated by exogenous prostaglandin E2 (PGE2).

231 ted by indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2).

232 iety of lipid signaling molecules, including prostaglandin E2 (PGE2).

233 -2) pathway and the concomitant increases in prostaglandin E2 (PGE2).

234 nhancing ability of a short-term exposure of prostaglandin E2 (PGE2); this strategy has now progresse

235 as it converts 2-AG to the glycerol ester of prostaglandin E2 (PGE2-G).

236 Here we report that signaling through the prostaglandin-E2 (PGE2) EP4 receptor potently suppresses

237 protocol with bone morphogenetic protein 4, prostaglandin-E2 (PGE2), and StemRegenin 1 (SR1) for hem

238 Thus, the glyceryl ester of prostaglandin E2, PGE2-G, mobilizes Ca(2+) and activates

239 synaptic inhibition occur partially through prostaglandin E2- (PGE2-) and PKA-dependent phosphorylat

240 Prostaglandin E2, platelet-derived growth factor (PDGF)

241 DON-induced cyclooxygenase-2 expression and prostaglandin E2 production and pro-inflammatory cytokin

242 njunctiva (CNJ) of the mice was cultured for prostaglandin E2 production induced by sPLA2-IIa with va

243 e, gedunin (10 microM) inhibited LPS-induced prostaglandin E2 production, cyclooxygenase-2 expression

244 LPS-stimulated prostaglandin-E2 production was dysregulated in macropha

245 tion and lipid deposition, and to controlled prostaglandin-E2 production.

246 Prostaglandin E2 promotes cancer invasion, and in a feed

247 Prostaglandin E2 promotes not only immune tolerance and

248 Plasma levels of histamine, leukotriene B4, prostaglandin E2, prostaglandin F2, pH, and HCO3 were me

249 sphatidylcholine, lysophosphatidic acid, and prostaglandin E2) recapitulated M1 phenotype in iPLA2bet

250 Activation of prostaglandin E2 receptor (PGE(2)) subtype EP2 promotes

251 PGE(2) acted via prostaglandin E2 receptor 2 (EP(2)) and EP(4) to induce

252 els of acquired AI resistance indicated that prostaglandin E2 receptor 4 (PTGER4) is upregulated afte

253 of noscapine in HLFs were blocked by the EP2 prostaglandin E2 receptor antagonist, PF-04418948, but n

254 Further, mice lacking the prostaglandin E2 receptor EP3 selectively on serotonergi

255 Primary mouse microglia that lack prostaglandin E2 receptor subtype 2 (EP2) show decreased

256 nd first intron of the PTGER4 gene (encoding prostaglandin E2 receptor subtype 4; all P < 5 x 10(-5))

257 ed a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2, TG6-10-1, with a

258 el mechanism of noscapine action through EP2 prostaglandin E2 receptor-mediated activation of PKA in

259 n D2 receptors (DPs) DP1 (49) and DP2 (558), prostaglandin E2 receptors (EPs) EP1 (266) and EP4 (117)

260 resistance protein 4, and G-protein-coupled prostaglandin E2 receptors 1 and 2), abolished P-glycopr

261 Increased cyclooxygenase-2 expression and prostaglandin E2 release could be abrogated in metastati

262 oxyprostaglandin dehydrogenase, resulting in prostaglandin E2 release in human breast cancer.

263 s activators of PKA, including adenosine and prostaglandin E2, results in a profound delay of neutrop

264 ated cyclooxygenase-2 (COX-2) expression and prostaglandin E2 secretion, indicating a proinflammatory

265 g components in the cyclooxygenase-2 (COX-2)/prostaglandin E2 signaling cascade (phospholipase A2, CO

266 a mechanism involving caspase activation and prostaglandin E2 signaling.

267 Even in vitro, NRF2 activation or prostaglandin E2 supplementation blunted the induction o

268 Immunity, Coulombe et al. (2014) report that prostaglandin E2 suppresses innate and adaptive immune r

269 e been extensively investigated, identifying prostaglandin E2 synthase (mPGES)-1 and 5-lipoxygenase (

270 Microsomal prostaglandin E2 synthase (mPGES)-1 is responsible for t

271 S) 2, and fibronectin expression by HLFs and prostaglandin E2 synthase (PGE2S) expression by AECs wer

272 e were a coding variant in the gene encoding prostaglandin E2 synthase (PTGES2; P = 9.3 x 10(-5)) res

273 Microsomal prostaglandin E2 synthase type 1 (mPGES-1) is responsibl

274 Dual inhibition of microsomal prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase

275 Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ide

276 also been linked to asthma, where deficient prostaglandin E2 synthesis has been associated with airw

277 The febrile response is triggered by prostaglandin E2 synthesis mediated by induced expressio

278 lic phospholipase A2, which was reflected in prostaglandin E2 synthesis.

279 into the role played by genetic variation in prostaglandin E2 synthetic and signaling pathways in PGD

280 sion induced by inflammatory pain depends on prostaglandin E2 that is synthesized by cyclooxygenase 2

281 t of diffusible signaling molecules, such as prostaglandin E2 The capability of human or murine CAFs

282 erinatal lethal with reduced brain levels of prostaglandin E2 The non-functional phospholipase A2-act

283 reversed hyperalgesia induced by intrathecal prostaglandin E2 To distinguish between a peripheral/spi

284 KSHV utilizes inflammatory cyclooxygenase 2/prostaglandin E2 to establish and maintain latency.

285 The whipworm (Trichuris suis) secretes prostaglandin E2 to suppress proinflammatory properties

286 We propose that tick salivary prostaglandin E2 triggers antibody class switching in ma

287 r the formation of the potent lipid mediator prostaglandin E2 under proinflammatory conditions, and t

288 rometry revealed the very specific nature of prostaglandin E2 up-regulation as the other analyzed AA

289 We also evaluated prostaglandin E2 urinary metabolite (PGE-M) in an indepe

290 Cyclooxygenase and lipoxygenase metabolites prostaglandin E2 (vasodilator) and 12-hydroxyeicosatetra

291 eukin-6, chemokine (C-C motif) ligand 5, and prostaglandin E2 was assessed by enzyme-linked immunosor

292 By contrast, the induction of ID1 by prostaglandin E2 was mediated by cAMP response element-b

293 However, responses to prostaglandin E2 were decreased by CS exposure.

294 ls pulsed in vitro for 2 hours with dimethyl prostaglandin E2 were functionally similar to those from

295 e metabolites 11-hydroxyeicosatetraenoic and prostaglandin E2 were reduced by 80% to 90% in septic pa

296 ecursor self-renewal also was obtained using prostaglandin E2, which is downstream of cyclooxygenase

297 DUSP2 led to overproduction of COX-2-derived prostaglandin E2, which promoted cancer stemness via the

298 ocompetent host requires their production of prostaglandin E2, which suppresses immunity and fuels tu

299 induced increase in hippocampal and thalamic prostaglandin E2, while the COX-2-specific inhibitor NS-

300 the patients with low urinary metabolite of prostaglandin E2 who received celecoxib (HR = 1.57; 95%